DCVAC/OvCa

BIOLOGICAL4 trials

Sponsors

SOTIO a.s., Peking University Third Hospital

Conditions

Epithelial Ovarian CarcinomaFallopian Tube CancerFallopian Tube CarcinomaOvarian CancerOvarian Cancer RecurrentPeritoneal CarcinomaPrimary Peritoneal Carcinoma

Phase 2

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

TerminatedNCT02107378

SOTIO a.s.Epithelial Ovarian Carcinoma

Start: 2014-01-31End: 2016-08-31Updated: 2016-11-30

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

CompletedNCT03657966

SOTIO a.s.Ovarian Cancer Recurrent

Start: 2017-11-23End: 2021-02-25Updated: 2021-04-21

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

RecruitingNCT04834544

Peking University Third HospitalEpithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma

Start: 2021-04-19End: 2027-04-20Target: 75Updated: 2021-05-03

Phase 3

DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

WithdrawnNCT03905902

SOTIO a.s.Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Carcinoma

Start: 2021-08-31End: 2021-08-16Updated: 2021-12-23